Evidence map›Paper›PMID 33993429›Full record

ArticleClinical journal of gastroenterology2021

Marked reduction in the number of white globe appearance lesions in the noncancerous stomach after exchanging vonoprazan for esomeprazole treatment: a follow-up case report.

Wataru Miwa, Takashi Hiratsuka, Ken Sato, Takashi Fujino, Yo Kato

Erratum issuedAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The role of vonoprazan in patients with erosive esophagitis.Therapeutic advances in gastroenterology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Wataru MiwaDivision of Internal Medicine, Hiratsuka Gastroenterological Hospital, 3-2-16 Nishiikebukuro Toshima-ku, Tokyo, 171-0021, Japan. wmiwa@ichou.gr.jp.
Takashi HiratsukaDivision of Internal Medicine, Hiratsuka Gastroenterological Hospital, 3-2-16 Nishiikebukuro Toshima-ku, Tokyo, 171-0021, Japan.
Ken SatoDivision of Surgery, Hiratsuka Gastroenterological Hospital, Tokyo, Japan.
Takashi FujinoDepartment of Cancer Genomic Medicine, Saitama Medical University International Medical Center, Saitama, Japan.
Yo KatoDivision of Pathology, Hiratsuka Gastroenterological Hospital, Tokyo, Japan.
Hiratsuka City Hospital · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, an association has been suggested between development of white globe appearance lesions in the noncancerous stomach and treatment with a potassium-competitive acid blocker or a proton pump inhibitor. We previously reported two cases with development of white globe appearance lesions after vonoprazan treatment, suggesting a similar association. Here, we present the follow-up report of one of those two cases, concerning a 68-year-old woman who developed multiple white globe appearance lesions 1 year after starting vonoprazan treatment for severe gastroesophageal reflux disease leading to esophageal stricture. The patient refused to continue vonoprazan treatment after the lesions developed, and esomeprazole was initiated instead. Three months later, most of the white globe appearance lesions had disappeared, without worsening of her gastroesophageal reflux disease. Histologically, mucosal structural changes induced by vonoprazan, such as parietal cell protrusion with oxyntic gland dilatation, remained unchanged, whereas the gastric glands became less packed and a small calcification in the concentrated eosinophilic material was observed in a remaining white globe appearance cyst after esomeprazole treatment. Here, we discuss possible pathogenic mechanisms of these dramatic gastric mucosal changes observed in the present case, based on our endoscopic and histological findings.

Indexed as

EsomeprazolePyrrolesAgedFemaleFollow-Up StudiesHumansProton Pump InhibitorsStomachSulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineEsomeprazoleProton Pump InhibitorsPyrrolesSulfonamidesEsomeprazoleParietal cell protrusionVonoprazanWhite globe appearance

Identifiers

PMID33993429
OpenAlexW3160556467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.